Painchek Ltd (ASX: PCK) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

PainChek Ltd. Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $71.30 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 1.13 billion
Earnings per share -0.006
Dividend per share N/A
Year To Date Return -24.68%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

Painchek Ltd (ASX: PCK)
Latest News

PCK ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Painchek Ltd

Painchek Ltd is engaged in the development and commercialization of mobile medical device applications, that automate intelligent pain assessment of individuals who are unable to communicate pain with carers. It operates in one segment namely sale of pain assessment solutions.

PCK Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
02 Dec 2021 $0.06 $0.00 0.00% 1,367,503 $0.06 $0.06 $0.05
01 Dec 2021 $0.06 $-0.01 -15.63% 1,964,075 $0.07 $0.07 $0.06
30 Nov 2021 $0.06 $0.00 0.00% 4,286,440 $0.06 $0.07 $0.06
29 Nov 2021 $0.07 $0.00 0.00% 5,916,645 $0.06 $0.07 $0.06
26 Nov 2021 $0.06 $0.02 44.44% 8,769,942 $0.05 $0.06 $0.05
25 Nov 2021 $0.05 $0.00 0.00% 1,152,846 $0.05 $0.05 $0.05
24 Nov 2021 $0.05 $0.00 0.00% 841,404 $0.05 $0.05 $0.05
23 Nov 2021 $0.05 $0.00 0.00% 343,124 $0.05 $0.05 $0.05
22 Nov 2021 $0.05 $0.00 0.00% 106,382 $0.05 $0.05 $0.05
19 Nov 2021 $0.05 $0.00 0.00% 1,052,922 $0.05 $0.05 $0.05
18 Nov 2021 $0.05 $0.00 0.00% 1,555,515 $0.05 $0.05 $0.05
17 Nov 2021 $0.05 $0.00 0.00% 814,061 $0.05 $0.05 $0.05
16 Nov 2021 $0.05 $0.00 0.00% 509,099 $0.05 $0.05 $0.05
15 Nov 2021 $0.05 $0.00 0.00% 546,794 $0.05 $0.05 $0.05
12 Nov 2021 $0.05 $0.00 0.00% 325,696 $0.05 $0.05 $0.05
11 Nov 2021 $0.05 $0.00 0.00% 4,996 $0.05 $0.05 $0.05
10 Nov 2021 $0.05 $0.00 0.00% 1,065,591 $0.05 $0.05 $0.05
09 Nov 2021 $0.05 $0.00 0.00% 768,902 $0.05 $0.05 $0.05
08 Nov 2021 $0.05 $0.00 0.00% 1,357,200 $0.05 $0.05 $0.05
05 Nov 2021 $0.05 $0.00 0.00% 180,676 $0.05 $0.05 $0.05
04 Nov 2021 $0.05 $0.00 0.00% 416,630 $0.05 $0.05 $0.05
03 Nov 2021 $0.05 $0.00 0.00% 341,284 $0.05 $0.05 $0.05

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
15 Sep 2021 Adam Davey Issued 396 $20,000
Issue of securities. 602,436 - performance rights
Non-cash value
15 Sep 2021 Philip Daffas Issued 3 $200,000
Issue of securities. 6,957,623 - performance rights
Non-cash value
15 Sep 2021 John Murray Issued 792 $40,000
Issue of securities. 1,204,870 - performance rights
Non-cash value
15 Sep 2021 Ross Harricks Issued 396 $20,000
Issue of securities. 602,436 - performance rights
Non-cash value

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Adam Stuart Davey Non-Executive Director Sep 2014
Mr Davey is a Director of Wealth Management at Canaccord Genuity Patersons Limited. Mr Davey has been involved in growing businesses in both the industrial and mining sector. Mr Davey's expertise spans over 25 years and includes capital raising (both private and public), mergers and acquisition, ASX listings, asset sales and purchases, transaction due diligence and director duties. This has been achieved through holding various roles within different organisations, including chairman, managing director, non-executive director, major shareholder and corporate adviser to the board. Mr Davey is a non-executive director of Ensurance Limited and the Agency Group Australia Ltd.
Mr Philip Daffas Managing Director Sep 2016
Mr Daffas is a global business leader and people manager with an international career spanning more than 25 years with leading blue-chip healthcare corporates and novel technology start-up companies. Philip has held senior global business leader positions in Europe, US and Australia. He has been instrumental in building businesses, growing market share and developing extensive high-level customer and industry relationships in each sector on a global basis. Philip's earlier experience was gained in Europe with market leaders such as IVAC infusion systems and Shiley cardiopulmonary products. He subsequently joined Boehringer Mannheim, initially in the UK managing their diagnostics business and subsequently was promoted to a Global Marketing role in the Diabetes Care business cased in Mannheim, Germany. In 1997 Philip joined Cochlear in the UK as the European Sales and Marketing Manager and subsequently was promoted in 2000 to the VP Global Marketing role based in Sydney, Australia Other roles in Australia have included General Manager with Roche Diagnostics, Managing Director at Bio-Rad Laboratories and CEO of Applied Physiology, an Australian software start up company in the intensive care monitoring sector.
Mr John Murray Non-Executive ChairmanNon-Executive Director Sep 2016
Mr Murray has 25 years experience in private equity and venture capital and was a co-founder and Managing Partner of Technology Venture Partners; one of the original and leading venture capital firms in Australia. Mr Murray is a past chairman of the Australian Venture Capital Association. Mr Murray has considerable experience as an investor and a non-executive director of high growth, technologybased companies. He possesses a broad understanding of global trends in technology and its impact on a variety of industries. He is a past Chairman of a private, residential aged care business in Australia. Mr Murray also brings 12 years experience in executive roles in corporate banking, accounting and IT services industries. Mr Murray has been on the Board of a number of successful technology rollouts and exits including online travel play Viator, which was acquired by TripAdvisor for approximately US$200 million in 2014. Mr Murray is a director of UK AIM listed company Seeing Machines Ltd.
Mr Ross Harricks Non-Executive Director Sep 2016
Mr Harricks has experience in the commercialisation of medical products which spans over forty years and over three continents. His experience includes the marketing and commercialising of the computed technology scanner (CT or CAT scanner) in Australia, where he headed up the EMI Electronics Group as General Manager. His remit included developing EMI's medical business in this region. In 1983, Mr Harricks joined the Nucleus Group as Group Marketing Executive, and later became President the two Nucleus Group subsidiaries in United States marketing medical equipment and scientific and engineering computing products. In 1989 in the US, Mr Harricks was the CEO of a venture capital-backed start-up company developing specialist scientific and medical lasers. In Australia Mr Harricks has been a director of ResMed Limited and cofounder of AtCor Medical where he completed an Australian initial public offering in 2005 leading the company until 2007. He was a director of VentraCor from 2005 to 2009. Mr Harricks works with Australian medical and technology companies assisting in commercialisation of their products into the US and EU markets. His unique expertise and experience includes strategic advising on the best path to early international market endorsement and adoption, and on providing hands-on help with implementation in the American and European markets.
Ms Sally McDow Company Secretary Jun 2021
-
Iain McAdam Chief Financial Officer
-
Sally McDow Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Peters Investments Pty Ltd 113,000,000 9.98%
HSBC Custody Nominees (Australia) Limited 41,338,803 3.65%
J&E Consulting Pty Ltd 37,003,125 3.27%
Dr Kreshnik Hoti 37,003,125 3.27%
Mr Mustafa Abdul Wahed Atee 37,003,125 3.27%
BNP Paribas Nominees Pty Ltd Six Sis Ltd <Drp A/C> 26,033,862 2.30%
Mr Philip Daffas 20,499,581 1.81%
Thornbury Nominees Pty Ltd <The Stevens Family S/F A/C> 15,050,000 1.33%
G & G Chilcott Pty Ltd <G & G Chilcott S/F A/C> 13,927,169 1.23%
Mr Robert Anthony Healy 12,857,143 1.14%
Nanjop Pty Ltd <The Murring Family A/C> 12,299,748 1.09%
Mr Allan Graham Jenzen & Mrs Elizabeth Jenzen <Ag & E Jenzen P/L No2 Sf A/C> 12,277,974 1.08%
Citicorp Nominees Pty Limited 11,890,945 1.05%
Capper Superannuation Pty Ltd <Capper Super Fund A/C> 11,674,331 1.03%
Xtreme Nominees Pty Ltd <The Investment Unit A/C> 11,654,791 1.03%
Mr Robert Anthony Healy i 11,000,000 0.97%
Ms Eloise Kathleen Jennings & Mr Andrew John Hopkins <Jennings Hopkins Discret A/C> 10,599,791 0.94%
Ms Eloise Kathleen Jennings & Mr Andrew John Hopkins <Jennings Hopkins S/F A/C> 10,486,709 0.93%
Bradan Investments Pty Limited <Mcguirk Family A/C> 10,000,000 0.88%
Mr Craig Robert Williamson 9,433,000 0.83%

Profile

since

Note